HDAC9 and cancer: HDAC inhibitors are closely associated with immunotherapy; they can enhance the expression of cancer antigens, decrease immunosuppressive cell populations like the myeloid-derived suppressor cell, regulate specific suppressive pathways, and induce specific chemokine expression on T cells (Banik et al., 2019).